NCT02312102View on ClinicalTrials.gov

Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

April 30, 2017

Study Completion Date

October 7, 2024

Conditions
Myelodysplastic SyndromeAcute Myeloid Leukemia
Interventions
DRUG

Lenalidomide

Chemotherapy

DRUG

Velcade

Chemotherapy

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER